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Summary
Objective: To evaluate the prevalence of resistance mutations in the genome of HIV-1 F subtype
strains isolated from Romanian antiretroviral (ARV) treatment-naı¨ve patients and to assess the
phylogenetic relatedness of these strains with other HIV-1 strains.
Methods: Twenty-nine HIV-1 strains isolated from treatment-naı¨ve adolescents (n = 15) and
adults (n = 14) were included in this study. Resistance genotyping was performed by using Big
Dye Terminator chemistry provided by the ViroSeq Genotyping System. The sequences of the
protease and reverse transcriptase genes were aligned (ClustalW) and a phylogenetic tree was
built (MEGA 3 software). For subtyping purposes, all the nucleotide sequences were submitted to
the Stanford database.
Results: All the studied strains were found to harbor accessory mutations in the protease gene.
The most frequent mutation was M36I (29 of 29 strains), followed by L63T, K20R, and L10V. The
number of polymorphisms associated with protease inhibitor resistance was different for the two
age groups. Intraphylogenetic divergence was greater for adults than for adolescents infected in
childhood. All the strains were found to belong to the F1 subtype. The phylogenetic analysis
revealed that Romanian strains clustered together, but distinctly from F1 HIV-1 strains isolated in
other parts of the world (Brazil, Finland, and Belgium).
Conclusion: Protease secondary mutations are present with high frequency in the HIV-1 F subtype
strains isolated from Romanian ARV treatment-naı¨ve patients, but no major resistance mutations
were found.
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With the advent of highly active antiretroviral therapy
(HAART) the life expectancy of HIV infected patients has been
significantly prolonged. However, it is now clear that muta-
tions accumulate in treated patients, limiting the efficacy of
the therapy and requiring adjustments of the antiretroviral
regimen. Resistance genotyping has become standard of care
in HIV infection management.1 Resistance mutations are
reported with increasing frequencies in treatment-naı¨ve indi-
viduals.2—5 The prevalence of major resistance mutations for
any antiretroviral drug observed in recent seroconverters can
range from 2% to 26% in North America, 23% to 26% in Spain, 4%
to 17% in France, and 5% to 11% in Switzerland.3 Information
has accumulated so far mainly on type M subtype F strains
whicharepredominant in theWesternhemisphere.An increas-
ing number of communications have shown that resistance
mutations can occur spontaneously in the genome of viruses
belonging to subtypes other than B isolated from untreated
patients.6—8 Most of these mutations are polymorphisms and
are considered secondary mutations that by themselves play a
limited, if any, role in resistance.However, their pre-existence
might favor a more rapid evolution towards resistance when
additional mutations are selected under therapy.
Since 1992, the HIV-1 strains isolated from patients world-
wide have been classified into three distinct genetic groups: M
(major) group, O (outlier) group, and N (non-M, non-O) group.
Within the M group nine subtypes have been identified so far
(A, B, C, D, F, G, H, J, and K) and intersubtype circulating
recombinant forms (CRFs) and unique recombinant forms
(URFs) have been described. Since most of the therapeutic
experience has been derived from HIV-1 subtype B infections,
the management of patients infected with HIV-1 strains of
subtypes other than B is mostly the result of extrapolation.
In this study we present data obtained from the analysis of
strains isolated from Romanian treatment-naı¨ve adolescents
and adults. Previous anecdotal information has suggested that
subtype F strains are rather common in Romania.9,10 Our
findings have confirmed these observations (the vast majority
of the strains tested so far belong to the F subtype), although
the strains displayed several dissimilarities with subtype F
strains originating from other geographical regions. A recent
study11 has evaluated the subtype impact on polymorphism
and resistance mutation development under ARV treatment
and it has concluded that the positions associated with drug
resistance for theB subtypeare not significantlydifferent from
those found in other HIV-1 subtypes; however, the number of
polymorphisms was higher in non-B subtype HIV-1 strains.
Preliminary data indicated that theHIV-1 strains fromRomania
clustereddistinctlywithin theF subtype.12 Itwas thereforeour
purpose to assess the frequency of resistance mutations spon-
taneously occurring in the genome of the Romanian subtype F
strains and to compare the relatedness of several subtype F
strains isolated from naı¨ve patients in Romania with other
strains of subtype F and other subtypes.
Methods
Study population
We studied 29 HIV-1 strains isolated from Romanian patients,
adolescents (n = 15) and adults (n = 14), originating from dif-ferent regions of the country. All of the adolescents were the
same age (14—15 years old) and most of the available epide-
miological data suggest that they were infected by contami-
nated blood products of improper sterilization of needles used
for parenteral treatment. The adults were all infected by the
heterosexual route. The studiedpatientswereARV treatment-
naı¨ve at the time when the blood samples were drawn.
Clinical specimens
Plasma samples were obtained from the 29 HIV-1 infected
patients. For all the patients the viral loads were higher than
10 000 copies/mL. Five mL of blood were collected in EDTA
and the plasma was separated by centrifugation at 850 g for
15 min. The samples were frozen at 80 8C for storage until
the RNA extraction.
Sequencing
The ViroSeq HIV-1 genotyping system (Celera Diagnostics,
Alameda, USA) was used according to the manufacturer’s
recommendations, with the exception of the RNA extraction
which was performed with the Abbott m1000
TM
automatic
nucleic acid extraction instrument. Briefly, after the deter-
mination of the viral load by LCx HIV RNA quantitative assay
(Abbott Laboratories, Abbott Park, USA), the extracted RNA
was reverse transcribed and then amplified by PCR. The
thermal cycling was performed on a GeneAmp System 9700
(Applied Biosystems, Foster City, USA) thermal cycler. The
1.8 kb RT-PCR product was purified using MicroCon YM-100
concentrators (spin columns). The purity and the amount of
the DNA amplification product were evaluated by running an
aliquot on a 1% agarose electrophoresis gel. The amplicon
was diluted to a standard 20—40 ng/sequencing reaction.
Big Dye Terminator chemistry was used for DNA sequen-
cing: seven sequencing reactions were set up for covering the
entire HIV-1 protease (PR) gene and two-thirds of the reverse
transcriptase (RT) gene.
Capillary electrophoresis of the samples was performed on
an ABI Prism 3100-Avant Genetic Analyzer (Applied Biosys-
tems). Prior to loading, the purified products of the sequen-
cing reactions were resuspended in formamide, denaturated
at 95 8C/2 min and chilled on ice. The raw analysis of the
sequences was made using Sequencing Analysis software
version 3.7 and then they were assembled with ViroSeq
2.5 HIV-1 Genotyping System software. The correctness of
each electropherogram interpretation was validated by the
operator and the sequences were saved in Fasta format. The
resistance report generated by ViroSeq provides a list of
nucleotide mutations detected in the PR (codons 1—99)
and the RT gene (codons 1—335) known to determine resis-
tance to antiretroviral drugs and infers a resistance profile
for each strain. The Fasta files were then used to interpret
the results by the HIV Seq Program (HIV-1 RT and protease
search engine of queries), available at the Stanford database
(http://hivdb.stanford.edu). The same resistance mutations
were identified by both Viroseq 2.5 and Stanford software.
Phylogenetic and sequence analysis
The subtyping of all the Romanian strains was done by using
the publicly available algorithm at the Stanford database
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Table 1 Amino acid substitutions in the protease gene sequences of HIV-1 F subtype Romanian strains at positions associated with
resistance to protease inhibitors
Codon position Subtype B amino acid Amino acid substitution No. of strains Percentage
10 L V 13 44.8
I 2 6.9
IL/VL 2 6.9
20 K R 21 72.4
M 1 3.4
36 M I 29 100
63 L T 27 93.1
AT 1 3.4
77 V I 1 3.4
82 V I 1 3.4
93 I L 4 13.8
Figure 1 The distribution of PI-resistance associated poly-
morphisms in HIV-1 Romanian strains isolated from adolescents
(gray boxes) and adults (black boxes). The two series were found
to be different when compared with Fisher’s exact test
(p < 0.02).(Rega HIV-1 subtyping tool version 1.0). The nucleotide
sequences were translated into protein sequences in order
to identify amino acid changes. The alignment of our
sequences and the reference sequences of HIV-1 group M,
subtype B, F1, F2 available in the Los Alamos HIV-1 database
(www.hiv.lanl.gov) was performed using ClustalW multiple-
sequence alignment software. The reference sequences used
for the phylogenetic tree were as follows: HXB2 (reference
strain for the B subtype), three F1 Brazilian strains (BZ163
AY173958, BZ126 AY173957, and 93BR020 AF005494which
is representative for the F subtype), a further two F1 Eur-
opean strains (FIN9363 AF075703 and VI850 AF077336), and
four F1 Romanian strains (97R101 AF204010, 96R96
AF204004, 93R26 AF203986, and 97R105 AF204014). We
also included in this analysis four F2 strains isolated from
Cameroon (95CM-MP257C AJ249237, 95CM-MP255C
AJ249236, CM53657 AF377956, and 02CM0016BBY
AY371158). Because all the Romanian sequences identified
from the Los Alamos HIV-1 database were shorter (the first
five codons of the PR gene were missing) our nucleotide
sequences were trimmed to equivalent lengths (1149 n),
representing 94 of the 99 PR gene codons and the first 289
codons of the RT gene. The phylogenetic analysis of all the
sequences was made by using the neighbor-joining method as
performed by the MEGA 3 software.13 The distance matrix
was generated by Kimura’s two parameter model for nucleo-
tides. The statistical strength of the neighbor-joining method
was assessed by bootstrap resampling (1000 replicates). We
used as outgroup the sequence of HIV-1 group O (MVP5180
L20571).
Our sample names are according to the WHO/UNAIDS
nomenclature, indicating the year of isolation, the country
of origin (two letter codes) and the isolate number.
Results
In order to detect mutations that confer resistance to pro-
tease inhibitors (PI), we compared the entire amino acid
protease sequences of each strain included in this study with
the subtype B consensus sequence (Stanford HIV database).
We could not detect any primary mutations (D30N, G48V,I50V, V82A/T/F, I84V, L90M). However, secondary mutations
were found in all 29 strains and affected six positions: codons
10, 20, 36, 63, 77, and 93 (Table 1). The most frequent
mutation encountered was M36I present in all the PR
sequences. It was followed by L63T (93.1%; 27 of 29),
K20R (72.4%; 21 of 29), and L10V (44.8%; 13 of 29). Previous
studies suggested that M36I represents a molecular signature
for non-B strains, particularly for the F subtype, whereas
L63P is a distinct mark for B strains.3,14 In our study, sub-
stitutions at positions 36 and 63 occurred with very high
frequencies.
All the sequenced strains had accessory resistance muta-
tions that had been previously described as polymorphisms in
the protease gene. Two mutations were present in one of 29
strains (3.4%), three mutations in 14 of 29 strains (48.2%),
four mutations were found in 12 of 29 (41.3%) sequences and
two strains (6.8%) had five mutations. The polymorphisms
were not evenly distributed in the adolescent and adult
groups (Figure 1). In certain positions that are known to
be associated with PI resistance we observed other muta-
tions, different from those involved in resistance. For exam-
ple, V82I (sample 04RO523c) or L63A (sample 04RO4983) are
known to have little or no impact on PI susceptibility.14
In contrast with the protease gene, the analysis of 289
codons of the RT revealed no major and very few accessory
126 S. Paraschiv et al.mutations. The mutations associated with resistance to
nucleoside reverse transcriptase inhibitors (NRTIs) and
non-nucleoside reverse transcriptase inhibitors (NNRTIs)
have been well characterized and differ between these
two classes of RT inhibitors: resistance mutations to NRTIs
are localized in ‘fingers’, ‘thumb’, and ‘palm’ domains of the
reverse transcriptase while mutations responsible for resis-
tance to NNRTIs are localized into the hydrophobic cavity
(NNRTI binding site). The V179D mutation appeared in only
two of the samples (04RO2165 and 04RO2301) isolated from
adults. Low-level resistance to each NNRTI has been attrib-
uted to this mutation, but its effect is considered insignif-
icant in the absence of other mutations. In the RT gene we
identified some atypical mutations at key positions known to
be linked with drug resistance, namely M41R (03RO155),
T69AT (03RO1436), Y318I (03RO155), and K101RK
(04RO4420), but these mutations have not been reported
as important for resistance to NRTIs or NNRTIs.
Phylogenetic analysis
The subtype analysis of the PR and RT sequences indicated
that all 29 HIV-1 strains belonged to the F1 subtype, with a
bootstrap support ranging between 76% and 100%. The 1149
nucleotide sequences of the 29 Romanian strains represent-
ing the PR gene and half of the RT gene were used to build a
phylogenetic tree. Our strains were compared with reference
strains of different subtypes (B, F1, F2) and sequences of HIV-
1 strains isolated between 1993 and 1997 from Romanian
patients, available in the Los Alamos HIV-1 sequence data-
base. We used as outgroup the MVP5180 sequence (HIV-1
group O). The result of the phylogenetic analysis is presented
in Figure 2. As expected, the algorithm could efficiently
discriminate among different subtypes. The studied strains
clustered with the F1 reference strains and were distinct
from the F2 strains. Moreover, all the Romanian strains
clustered together with the other Romanian strains identified
from the Los Alamos HIV-1 sequence database, but were
distinct from F1 Brazilian strains or F1 European strains
(Belgium and Finland), suggesting a different epidemiologi-
cal context for the infection.
The phylogenetic analysis did not discriminate between
the HIV-1 strains isolated from the two age groups. However,
the average sequence divergence was higher in the adult
group (6.49%) in comparison with the adolescent group
(5.11%).
It has been shown that although the pol gene is very
conserved, it can be used for subtyping purposes. Our data
confirm this observation and, furthermore, show that the
gene can discriminate between groups of strains belonging to
the same subtype (Romanian and Brazilian F strains clustered
distinctly).
Discussion
Recent studies have tried to assess the influence that differ-
ent HIV-1 subtypes exert on the efficacy of ARV treatment and
the progression to AIDS.14—16 The results have often been
contradictory, but there is evidence that strains belonging to
group O are naturally resistant to NNRTIs and some G subtype
strains are less susceptible to PIs.17,18Most of the RT and PR resistance data reported to date
originate from HIV-1 B subtype studies — this being the
predominant subtype in Western Europe and North America.
The dominant subtype responsible for HIV infections in Roma-
nian children and adults is the F subtype.9,19 It has also been
reported, with lower prevalence, in other countries like
Brazil, Argentina, Cameroon, France, and Belgium. Phyloge-
netic analysis of the HIV-1 strains isolated from these differ-
ent countries suggest that separate epidemiological factors
contribute to the particular distribution of HIV-1 F subtype in
distinct regions of the world.2,12,20
In Romania, epidemiological data suggest that children
have been infected by contaminated blood products and/or
improper sterilization of needles used for parenteral treat-
ment (vaccination). Most of the viral transmission in adults is
by the heterosexual route. To better understand the epide-
miological context of the HIV infection in Romania, we
performed a phylogenetic analysis of strains isolated from
two distinct age groups. Phylogenetic trees are powerful
tools that evaluate the relatedness of field strains. Our
results show that all the HIV strains isolated from adults
and adolescents infected in childhood clustered together
into a distinct group. For comparison purposes, PR and RT
sequences of F1 and F2 subtypes collected from South
America and Europe were included in our analysis. The
resistance-associated mutations in the PR gene were differ-
ently distributed in the adolescent and adult groups: more
mutations were detected in strains from adult patients than
in those from adolescents (Figure 1). Differences between
strains isolated from these two age groups were also
observed when intrasubtype F sequence divergence was
calculated: the divergence was higher in strains originating
from adults. These data correlate well with the distinct
infective events in teenagers vs. adults: the adolescent
cohort, all between 14 and 15 years of age have presumably
been infected within a short span of time by the parenteral
route whereas the adults have been infected over a longer
period of time duringwhich the virus has had the opportunity
to evolve through bottleneck events during interhuman
transmission.
None of the subjects included in this study had received
any antiretroviral treatment. In order to investigate the
impact of HIV-1 F subtype on resistance before the onset
of ARV treatment, we searched mutations known to be
associated with resistance to protease and reverse transcrip-
tase inhibitors. Overall, the protease gene appears to be less
conserved than the RT gene. No primary resistance mutations
were found, but every HIV strain analyzed was harboring at
least two accessory mutations. The M36I mutation in the
protease gene (associated with resistance to ritonavir and
nelfinavir in B subtype viruses) was found in all the Romanian
strains. This finding supports the suggestion that methionine
in this position may represent a polymorphism specific to the
B subtype. Substitutions were also observed in other protease
gene positions, some of them with rather high frequency: 10,
20, 63, 77, and 93.
Accessory mutations may not result in a significant
decrease of sensitivity to ARV drugs, but have been reported
to be associated with increased viral fitness in viruses with
primary mutations. It can therefore be speculated that the
selection of primary mutations under selective pressure
could precipitate the development of highly resistant HIV
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Figure 2 Phylogenetic analysis of PR and RT nucleotide sequences (1149 bp) from 29 Romanian strains and reference strains available
in the Los Alamos HIV-1 database. The tree was generated as described in the Methods. The reference strains are presented in the same
section and are distinctly marked (*). The numbers at the nodes indicate the percentage of the bootstrap value.
128 S. Paraschiv et al.variants during ARV treatment in viruses where one or more
secondary mutations are already present.
In this study direct sequencing of PCR products was per-
formed. Therefore, each sequence represents the consensus
genotype; it is possible that additional mutations may exist in
these HIV isolates, but PCR cloning followed by sequencing
would be necessary to detect them.
Kantor et al.11 have recently evaluated the frequency of
polymorphisms and resistance mutations in protease and
reverse transcriptase genes in non-B subtypes. Our findings
show a higher frequency of protease polymorphisms that are
secondary resistance mutations as well. We interpret this
observation as due to the higher homogeneity of the strains
we examined (only 18% of the subtype F strains analyzed by
Kantor et al. were isolated from Romanian patients).
Furthermore, this higher frequency correlates with the
increased frequency of the same polymorphisms as detected
in viruses isolated from Romanian treated patients (data not
shown).
In conclusion, no major mutations associated with resis-
tance to NRTIs, NNRTIs, and PIs were detected in subtype F
strains isolated from Romanian patients, but many accessory
substitutions were found as natural variants, mostly in posi-
tions associated with resistance to protease inhibitors. Their
incidence is partly different from that reported for other
subtype F HIV-1 strains. It is not yet clear if the high fre-
quency of accessory protease mutations may contribute to a
more rapid crossing of the genetic resistance barrier. Sequen-
tial phenotypic analyses and long-term follow-up of patients
under antiretroviral treatment will be necessary to evaluate
the clinical significance of these minor PR mutations.
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